Eli Lilly and Company $LLY Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. boosted its position in Eli Lilly and Company (NYSE:LLY) by 6.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 249,618 shares of the company’s stock after purchasing an additional 15,009 shares during the quarter. Eli Lilly and Company comprises approximately 0.6% of Mirae Asset Global Investments Co. Ltd.’s investment portfolio, making the stock its 23rd largest position. Mirae Asset Global Investments Co. Ltd.’s holdings in Eli Lilly and Company were worth $190,459,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Laurel Wealth Advisors LLC boosted its holdings in Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after purchasing an additional 11,537,661 shares during the last quarter. Norges Bank acquired a new position in Eli Lilly and Company during the 2nd quarter worth about $8,827,714,000. Vanguard Group Inc. grew its holdings in shares of Eli Lilly and Company by 1.5% in the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after purchasing an additional 1,183,038 shares in the last quarter. Franklin Resources Inc. boosted its position in Eli Lilly and Company by 13.4% in the 2nd quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock valued at $3,715,913,000 after buying an additional 564,736 shares during the period. Finally, Canada Pension Plan Investment Board boosted its position in Eli Lilly and Company by 87.2% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,152,281 shares of the company’s stock valued at $898,238,000 after buying an additional 536,679 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Market bullishness tied to Lilly’s weight‑loss/diabetes leadership, strong fundamentals and strategic AI/drug discovery moves are cited as reasons for the stock surge. Here’s Why Eli Lilly (LLY) is Surging
• Positive Sentiment: Lilly signed an agreement worth up to $1.12 billion with Germany’s Seamless Therapeutics to develop gene‑editing treatments for hearing loss — a sizable, longer‑term pipeline bet that supports upside if programs progress. Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless
• Neutral Sentiment: MedPal AI won approval to supply Lilly, which could modestly support Lilly’s GLP‑1 weight‑loss distribution but is not a material near‑term earnings driver. MedPal AI Wins Direct Eli Lilly Supply Approval
• Neutral Sentiment: Clinical updates such as the pirtobrutinib trial completion mark pipeline progress but are incremental until later‑stage readouts. Pirtobrutinib trial completion
• Negative Sentiment: The CMS named multiple Lilly drugs for the next round of Medicare drug price negotiations, including the first Part B‑reimbursed products — a direct pricing risk that could pressure future revenue/margins if negotiated discounts are large. US Medicare names Eli Lilly drugs for next Medicare price talks
• Negative Sentiment: Data show Novo Nordisk nearly doubled U.S. ad spend for Wegovy/Ozempic versus Lilly’s GLP‑1s in 2025, signaling intensified marketing competition that could pressure Lilly’s market share and require higher promotional spending. Novo’s Wegovy and Ozempic US advertising spend doubles rival Eli Lilly
• Negative Sentiment: The American Hospital Association urged federal action to block Lilly’s new 340B claims‑data submission policy, highlighting regulatory and hospital relationship friction that could create distribution/ reimbursement friction. AHA urges HRSA to stop Eli Lilly’s 340B claims-data submission policy

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on LLY shares. Zacks Research upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 1st. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Wednesday, January 14th. HSBC reissued a “hold” rating and set a $1,070.00 target price on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Guggenheim dropped their price target on shares of Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating on the stock in a research note on Tuesday, January 20th. Finally, Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Four analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Buy” and a consensus target price of $1,173.91.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,021.83 on Wednesday. The firm’s 50-day simple moving average is $1,058.15 and its 200 day simple moving average is $885.09. The firm has a market capitalization of $966.01 billion, a PE ratio of 49.85, a P/E/G ratio of 0.80 and a beta of 0.35. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the prior year, the company earned $1.18 EPS. Eli Lilly and Company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.